On September 26, 2024, the FDA told people with sickle cell disease who were taking Oxbryta to contact their health care professional about stopping it and starting another treatment (FDA, 2024). Oxbryta had reached the market almost 5 years earlier on the strength of a single measurement, a rise in hemoglobin, and the trials that came after it showed more pain episodes and deaths in people taking it (EMA, 2025). In August 2026, Pfizer wrote that there is not a viable path to make Oxbryta available again in the U.S. (Pfizer, August 2026).
By February 1, 2027, the FDA is due to decide on mitapivat for sickle cell disease, 3 months later than first planned. Agios Pharmaceuticals filed it under the same accelerated approval pathway, and the main evidence is again hemoglobin. In the 207-person RISE UP Phase 3 trial, 40.6% of people taking mitapivat had a hemoglobin response compared with 2.9% on placebo. Pain crises, the trial's other main goal, ran at 2.62 a year on mitapivat and 3.05 on placebo, a difference that did not reach statistical significance (Agios, November 2025).
Why the FDA Moved the Mitapivat Sickle Cell Decision to February 1, 2027
The FDA moved its goal date for mitapivat in sickle cell disease from November 1, 2026 to February 1, 2027 because it is weighing whether the drug needs a REMS, a required safety program. Agios announced the new date on October 30, 2026, and said the FDA's review is otherwise continuing, with labeling talks under way (Agios, October 30, 2026).
The sequence took 3 weeks. On October 9, the FDA asked Agios for information to judge whether a REMS is necessary for sickle cell disease, and Agios answered on October 19 with about 9 more months of safety data from the open-label extensions of its RISE UP trials (Agios, October 30, 2026).
On October 28, the FDA told Agios it was treating that answer as a major amendment to the application. Agios said that classification brings a 3-month extension, which is how November 1st became February 1st.
“The benefit-risk profile of mitapivat in sickle cell disease remains unchanged.”
Agios Pharmaceuticals, announcing the new goal date on October 30, 2026
Agios said that, with the longer follow-up, there are still no cases of liver injury in sickle cell patients on mitapivat that match the pattern and severity seen in its thalassemia trials. The company also said it is ready to launch and is discussing the label with the FDA, including elements of a potential REMS. The FDA has not said publicly what it will decide, and a REMS is a question the agency is still answering rather than a finding that one is needed.
What a REMS Is, and What Mitapivat's Thalassemia REMS Asks of Patients
A REMS is a drug safety program the FDA can require for certain medicines with serious safety concerns, built around 1 specific risk. The FDA says only a few medications require one, and most medicines rely on their label alone to describe risks (FDA, REMS).
Mitapivat already has a REMS for 1 use. The thalassemia version, sold as Aqvesme, can be prescribed only by doctors who enroll in the program and complete training, and those doctors must talk with each patient about the risk of liver injury (Aqvesme label).
Patients on Aqvesme enroll too and keep to a schedule of liver blood tests, taken before the first dose and every 4 weeks for the first 24 weeks. Only certified pharmacies can dispense it, and only to patients the program has authorized (Aqvesme label).
The FDA has not said whether a sickle cell approval would need the same program, a lighter one or none. The Aqvesme rules show the kind of steps a REMS can involve, and they are a fair basis for questions to bring to a hematologist once a decision is public.
The Thalassemia Review of Mitapivat Went Through the Same Step in 2025
Mitapivat's thalassemia application hit a similar step 13 months earlier. On September 4, 2025, Agios announced that the FDA had extended that review by 3 months, to December 7, 2025, after Agios submitted a proposed REMS for liver injury, which the FDA treated as a major amendment (Agios, September 2025).
Agios said at the time that the extension was not the result of new efficacy or safety data. The FDA approved the thalassemia use on December 23, 2025, with a boxed warning for liver injury and the REMS, under the new brand name Aqvesme (Agios, December 2025).
- 1Sep 4, 2025, day -3. Agios announces a 3-month extension after submitting a proposed REMS
- 2Dec 7, 2025, day +91. Extended goal date
- 3Dec 23, 2025, day +107. FDA approval, with the REMS
- 4January 2026, about day +141. Available in late January after the REMS was set up, according to Agios
- 1Oct 9, 2026, day -23. FDA asks whether a REMS is necessary
- 2Oct 28, 2026, day -4. FDA counts Agios's answer as a major amendment
- 3Feb 1, 2027, day +92. New goal date
In thalassemia, the FDA approved mitapivat 107 days after its original goal date, and the medicine reached patients about 5 weeks after that, once the REMS was in place. The sickle cell review now has a goal date 92 days after its original one. Trial Friend lined up the dates from Agios announcements of September 4, 2025, December 23, 2025 and October 30, 2026; 1 earlier review shows a path the process has taken, not a forecast of this decision.
The 2 cases are not identical. In thalassemia, Agios itself proposed the REMS after 5 people in its trials had reactions suggestive of liver injury. In sickle cell disease the FDA raised the question, and Agios answered with longer safety data that it says shows no matching cases.
The thalassemia launch also shows what a REMS can mean in practice. Agios reported in July 2026 that 442 Aqvesme prescriptions had been written by REMS-certified U.S. doctors by June 30, about 5 months after the medicine became available (Agios, July 30, 2026).
What the RISE UP Phase 3 Trial of Mitapivat Showed in Sickle Cell Disease
RISE UP randomly assigned 207 people aged 16 and older to mitapivat 100mg twice a day or a matching placebo, 2 on the drug for every 1 on placebo, and kept everyone blinded for 52 weeks (Agios, July 2026). A hemoglobin response meant an average rise of at least 1.0g/dL from week 24 through week 52. The 12-week Phase 2 part that came first enrolled people with any sickle cell genotype and a starting hemoglobin of 5.5 to 10.5g/dL. They had 2 to 10 pain crises in the year before joining, and 50% of those on the 100mg dose had a hemoglobin response against 4% on placebo (Lancet Haematology, 2025).
Some secondary numbers leaned in mitapivat's favor without counting as proof. Hospitalizations for pain crises ran at 1.56 a year on the drug and 1.81 on placebo, but the trial's testing order meant no statistical conclusion could be drawn (Agios, November 2025). At the European Hematology Association meeting in June 2026, Agios reported that 23.9% of people on mitapivat needed a blood transfusion in the trial, against 40.6% on placebo. People on mitapivat received 0.70 units per person against 1.59, and Agios said the difference held whether or not people also took hydroxyurea (Agios, June 2026).
Agios also split the mitapivat group by who reached a hemoglobin response. Responders averaged 2.20 pain crises a year and non-responders 2.98 (Agios, November 2025). That comparison was chosen after the results were in and looks only inside the mitapivat group, where the people who responded may have differed from the rest before they took a single dose, so it can point to a pattern without showing that the drug caused it.
““This drug is expected to help some people.” … I would want to know exactly how “some people” was determined, what exactly you used to determine who this helps.”
A participant at the FDA's 2014 patient meeting on sickle cell disease, The Voice of the Patient report
Mitapivat safety in RISE UP
Serious side effects were reported in 20.3% of people on mitapivat and 29.0% on placebo, and in 1 mitapivat patient the serious side effect was judged related to the drug. Side effects led 4.3% on mitapivat and 2.9% on placebo to stop treatment. There were 3 deaths on mitapivat, 2.2% of that group, and 2 on placebo, 2.9%, and investigators judged none of them related to treatment. Agios said liver test changes in the trial were not suggestive of drug-induced liver injury, unlike what its thalassemia trials had shown (Agios, November 2025).
Latest for Sickle Cell Disease
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
Free email alert
Want the next Sickle Cell Disease update without checking back?
We email you when a new Sickle Cell Disease trial opens or an FDA decision comes out.
You'll get trial alerts and disease updates for Sickle Cell Disease, and you can turn either off anytime. We never share your email. Privacy policy
Oxbryta Was Also Approved for Sickle Cell on Hemoglobin, Then Withdrawn
The FDA granted Oxbryta (voxelotor) accelerated approval on November 25, 2019. Its HOPE trial of 274 people measured one thing as its main goal: the share whose hemoglobin rose by more than 1g/dL at week 24, which was 51.1% on the 1,500mg dose and 6.5% on placebo. About 65% of HOPE participants were already taking hydroxyurea, and the FDA's notice said continued approval may depend on confirmatory trials (FDA, 2019).
- Nov 25, 2019Oxbryta gets accelerated approvalHemoglobin response of 51.1% vs 6.5% on placebo in the HOPE trial.
- Dec 17, 2021Oxbryta extended to ages 4 to 11Also an accelerated approval, based on hemoglobin in a 45-patient study.
- Sep 25, 2024Pfizer withdraws Oxbryta worldwidePfizer cited an imbalance in vaso-occlusive crises and fatal events.
- Oct 17, 2025Europe's advisory committee recommends the suspension stayIn a trial of children at higher risk of stroke, 8 on Oxbryta died and 2 on placebo.
- Nov 19, 2025Mitapivat Phase 3 resultsHemoglobin goal met, pain crisis goal not met.
- Jul 7, 2026FDA grants mitapivat priority reviewFiled under accelerated approval, with the confirmatory trial agreed in advance.
- Aug 4, 2026Pfizer says Oxbryta will not return in the U.S.Pfizer wrote that there is not a viable path to make it available again.
- Oct 30, 2026FDA extends the mitapivat review by 3 monthsThe FDA is weighing whether a REMS safety program is needed.
- Feb 1, 2027New FDA goal date for mitapivat in sickle cellMoved from November 1, 2026.
Hemoglobin is what the FDA calls a surrogate endpoint, a lab measurement “thought to predict clinical benefit, but is not itself a measure of clinical benefit” (FDA, accelerated approval). With Oxbryta the later evidence pointed the other way. Europe's medicines regulator closed its review in October 2025 and wrote that the newer trials showed more sudden pain episodes and deaths. It called those results “inconsistent with those of the earlier main clinical trial that supported” Oxbryta's approval, even though the final analysis of 2 patient registries did not confirm an increase in pain episodes (EMA, 2025).
Hematologists have argued about that lesson ever since. At the American Society of Hematology's annual meeting in December 2024, Harvard hematologist Maureen Achebe said the field has to wrestle with whether a rise in hemoglobin is a viable surrogate endpoint at all, and whether trials that move quickly from a short Phase 2 into Phase 3 gather enough safety data. RISE UP is that kind of combined Phase 2/3 trial. Others, like Mount Sinai's Jeffrey Glassberg, warned against overcorrecting (ASH Clinical News, February 2025).
“If you got rid of the accelerated approval process, the damage to people with SCD would be extraordinary. It's not diabetes; you can't get 50,000 patients into your study to get the data you need.”
Jeffrey Glassberg, MD, director of the Center for Sickle Cell Disease at Mount Sinai, ASH Clinical News, February 2025
Mitapivat is a different molecule aimed at a different target, and none of Oxbryta's history is evidence about it. What separates the 2 cases is trial design: Oxbryta's approval rested on hemoglobin alone, while mitapivat's Phase 3 tested pain crises as a second main goal for a full year and did not meet it, so the FDA is deciding with that result already on the table.
What the rules require of mitapivat that they did not require of Oxbryta
Congress rewrote parts of the accelerated approval rules in the Consolidated Appropriations Act, 2023, and FDA draft guidance now describes procedures for expedited withdrawal of an accelerated approval (FDA, accelerated approval guidance). Agios says its confirmatory trial must be underway when the FDA makes its decision, and it filed only after agreeing on that trial with the agency (Agios, May 2026). It dosed the first patient in the trial, called REIGNITE, by July 30, 2026 (Agios, July 30, 2026).
REIGNITE is testing transfusions, not pain crises, which children, parents and adults at the FDA's 2014 sickle cell patient meeting named among the most significant effects of the disease (FDA, 2014). Its main goal is the share of people who stay transfusion-free from week 4 through week 52, in about 159 people aged 12 and older given mitapivat 100mg twice a day or placebo, 2 to 1 (Agios, July 2026). If mitapivat is approved, whether it prevents pain crises will still rest on the RISE UP result described above.
Mitapivat Is Already Sold as Pyrukynd and Aqvesme, and Aqvesme Carries a Liver Warning
Mitapivat is not new to the FDA. It was approved as Pyrukynd for pyruvate kinase deficiency on February 17, 2022, and as Aqvesme for anemia in adults with alpha- or beta-thalassemia on December 23, 2025. Aqvesme's thalassemia trial used 100mg twice a day, the same dose tested in RISE UP (Agios, December 2025).
Aqvesme's label opens with a boxed warning that it can cause serious hepatocellular injury, meaning damage to the main cells of the liver. Liver tests are required at the start and every 4 weeks for 24 weeks, and the drug is available only through a restricted safety program called a REMS. In the thalassemia trials, 5 patients had reactions suggestive of liver injury and 2 of them were hospitalized; the problems appeared within the first 6 months and improved after the drug was stopped. Agios gave the thalassemia version its own brand name because of that REMS program (Agios, December 2025).
RISE UP did not show that pattern in sickle cell, according to Agios. Whether a sickle cell label carries the same boxed warning, the same REMS and the same brand name became the central open question of the review in October 2026, and the February 1st decision will answer it. Price is another. Agios put Aqvesme's U.S. list price for thalassemia at $425,000 a year and has not announced a price for sickle cell (Agios, December 2025 investor presentation).
How mitapivat works in sickle cell disease
Mitapivat switches on pyruvate kinase, an enzyme red blood cells use to make energy. That raises ATP, the cell's fuel, and lowers a molecule called 2,3-DPG. Agios says high 2,3-DPG raises the likelihood that red cells take on the sickle shape (Agios, July 2026). Lower 2,3-DPG also makes hemoglobin hold on to oxygen more tightly, and an April 2026 editorial in Annals of Translational Medicine noted the theoretical concern that this could reduce oxygen delivery to tissues and blunt the benefit. The same editorial pointed to Phase 2 data showing no rise in erythropoietin, a hormone the body makes when tissues run short of oxygen, as some reassurance (Annals of Translational Medicine, 2026).
Mitapivat vs Hydroxyurea, Gene Therapy, Etavopivat and Other Sickle Cell Treatments
Mitapivat would join a short list. Hydroxyurea remains the foundation: national guidelines recommend it for adults with sickle cell anemia who have 3 or more moderate to severe pain crises in a year and say to offer it to children from 9 months of age regardless of severity (NHLBI, 2014). The table below puts each option's own trial result next to its current status, and each approved option has its own page: hydroxyurea, L-glutamine, crizanlizumab, Casgevy and Lyfgenia.
| Treatment | How it is given | FDA status | Ages | What its main trial showed |
|---|---|---|---|---|
| Mitapivat | Pill, twice a day | Under review, decision due February 1, 2027 after a 3-month extension | Studied in 16 and older | Hemoglobin response in 40.6% vs 2.9%; pain crises not significantly reduced |
| Etavopivat | Pill, once a day | Not yet filed; Novo Nordisk plans to file in the second half of 2026 | Studied in 12 and older | 27% lower pain crisis rate; hemoglobin response in 48.7% vs 7.2% |
| Hydroxyurea (Droxia, Siklos, Xromi) | Pill or liquid, once a day | Approved | Siklos from age 2; Xromi liquid from 6 months | Recommended in national guidelines to prevent pain crises and other complications |
| L-glutamine (Endari) | Powder taken by mouth | Approved 2017 | 5 and older | Median of 3 hospital visits for pain crises vs 4 on placebo |
| Crizanlizumab (Adakveo) | IV infusion | Approved 2019; a newer trial did not establish benefit | 16 and older | The later STAND trial found no significant drop in crises vs placebo |
| Casgevy | One-time infusion of your own edited stem cells after high-dose chemotherapy | Approved 2023 | 2 and older since July 2026 | 29 of 31 evaluable patients went 12 months without severe crises |
| Lyfgenia | One-time infusion of your own modified stem cells after high-dose chemotherapy | Approved 2023, with a boxed warning for blood cancer | 12 and older | 28 of 32 had complete resolution of vaso-occlusive events over the measured period |
| Oxbryta (voxelotor) | Pill | Withdrawn September 2024; Pfizer says it will not return in the U.S. | Was 4 and older | Hemoglobin response in 51.1% vs 6.5%; later trials showed more crises and deaths |
Etavopivat is the closest comparison and the one to watch next. It works the same way as mitapivat, activating pyruvate kinase, and in Novo Nordisk's HIBISCUS Phase 3 trial of 385 people aged 12 and older it cut the yearly rate of pain crises by 27% compared with placebo and pushed the median time to a first crisis from 20.9 weeks to 38.4 weeks, with standard care allowed throughout (Novo Nordisk, April 2026). Its definitions differ from RISE UP's, so the 2 results cannot be lined up directly. Agios dropped its own second pyruvate kinase activator, tebapivat, from sickle cell development in July 2026 after Phase 2 results did not show a differentiated profile (Agios, July 21, 2026).
Adakveo, the crizanlizumab infusion, is still sold in the U.S., but its current label states that the efficacy of 2 doses was evaluated, but not established, in the STAND trial, and Europe revoked its authorization in 2023 (Adakveo label, 2024; EMA, 2023). For a full comparison of the 2 gene therapies, including price and eligibility, see our Casgevy vs Lyfgenia guide.
Hydroxyurea and Sickle Cell Clinical Trials: What 152 Trial Listings Say
Hydroxyurea is the standard treatment for sickle cell disease, so the rules about it decide who can join many trials. On September 29, 2026, we pulled every recruiting or not-yet-recruiting interventional study for sickle cell disease on ClinicalTrials.gov, 152 in all and 97 with a U.S. site, and read the eligibility text of each one that mentions hydroxyurea. Of those, 48 set a rule about it.
Of 152 recruiting or upcoming interventional sickle cell trials on ClinicalTrials.gov on September 29, 2026, 48 set a hydroxyurea rule: 19 allow it at a stable dose, 15 require that it failed, was not tolerated or was declined, 7 require stopping it, 6 study it and 1 requires it.
The stable-dose rule is the one most people on hydroxyurea will meet. Among the trials that name a length of time, the required time on a steady dose runs from 30 days to 6 months, and about 3 months is the most common, used by 8 of the 19. REIGNITE, mitapivat's confirmatory trial, asks for 90 days on a stable dose and a 90-day washout for anyone who stops, and it excludes people who took voxelotor, crizanlizumab or L-glutamine in the previous 90 days (ClinicalTrials.gov NCT07656415).
In most drug trials, starting hydroxyurea or changing the dose resets the stable-dose window, so a routine adjustment can push a possible trial start back by weeks or months. Mention trial plans when a dose change comes up, and see our analysis of medication rules across rare disease trials for how common this is beyond sickle cell.
Who the Mitapivat Decision Could Matter To, in 3 Situations
You were taking Oxbryta when it was withdrawn in 2024
The advice at the time came from both the company and the agency: Pfizer told patients to contact their physicians to discuss alternative treatment, and the FDA told patients and caregivers to talk with their health care professional about stopping Oxbryta and starting another option (Pfizer, 2024; FDA, 2024). Pfizer confirmed in August 2026 that Oxbryta is not coming back in the U.S. Akshat Jain, who directs the sickle cell center at Loma Linda University Health and had more than 60 patients on Oxbryta when it was pulled, told ASH Clinical News that most of them had not tolerated hydroxyurea or needed a second drug to reach their treatment goals. Bridget Reynolds, a patient in the same report who has the hemoglobin SC form of the disease and briefly took Oxbryta, said she might “wait and see” how patients do on any new sickle cell drug in the real world before trying it (ASH Clinical News, February 2025). Mitapivat reaches the FDA with a hemoglobin result of the same kind, plus a pain crisis result that fell short. If it is approved, the questions worth taking to your hematologist are what the label says it is for, whether it comes with liver monitoring, and whether your hemoglobin and crisis history look like those of the people in RISE UP.
You are 17 and weighing a daily pill against gene therapy
Casgevy has been approved for people 2 and older with recurrent pain crises since July 1, 2026, and Lyfgenia for people 12 and older (FDA, July 2026; FDA, 2023). Both start with collecting your own stem cells and end with high-dose chemotherapy before the modified cells go back in, and CMS notes that the gene therapy care journey typically results in infertility and covers egg, sperm and tissue preservation. In the 32 states plus Washington, D.C. and Puerto Rico that take part in the federal Cell and Gene Therapy Access Model, covering 84% of Medicaid enrollees with sickle cell disease, manufacturers must pay for fertility preservation for patients in the model, including storage for at least 5 years (CMS, CGT Access Model FAQ).
Mitapivat was studied in people 16 and older, so a 17-year-old fits the trial population, although the label will set who can get it. It would be taken every day with no chemotherapy, and it works on red cells already in circulation rather than changing the stem cells that make them. The gene therapies and mitapivat have never been compared in the same trial. The HBB gene page explains the gene behind sickle cell disease and lists trials that name it.
You take hydroxyurea and still have several pain crises a year
“We need new agents. We're down to blood transfusions and hydroxyurea because the other approved agents are being used much less frequently due to increased toxicity or limited tolerance.”
Crawford Strunk, MD, Cleveland Clinic, vice chief medical officer of the Sickle Cell Disease Association of America, ASH Clinical News, February 2025
RISE UP allowed people on a stable dose of hydroxyurea (Annals of Translational Medicine, 2026), and Agios says the lower transfusion rate held with or without it. Across the whole trial, though, mitapivat did not significantly reduce pain crises, the outcome this situation is about. Etavopivat did reduce them in its Phase 3 trial but has not been filed yet. REIGNITE and 4 etavopivat studies, 1 of them an extension for earlier participants, were recruiting when we checked ClinicalTrials.gov, and the sickle cell trial list shows those and others with their locations, with the hydroxyurea rules above as a guide to what each will ask.
What to Watch Before the February 1st Mitapivat Decision for Sickle Cell
February 1, 2027 is the FDA's new goal date, and the agency can act before it, approve the drug, or send a complete response letter asking for more. Agios reports third-quarter results on November 5, 2026, and the company may say more about the review then (Agios, October 2026).
If mitapivat is approved, 7 details will matter most: the exact wording of what it treats, the lowest approved age and whether it needs a REMS. The others are whether it carries Aqvesme's boxed liver warning, the brand name, the confirmatory trial requirement and the price Agios sets.
Novo Nordisk said in April 2026 that it plans to file etavopivat, the other pyruvate kinase activator, in the second half of 2026, and Trial Friend found no announcement of a filing as of October 30, 2026. The medical committee of the Sickle Cell Disease Association of America asked the FDA and drugmakers in August 2026 to measure patient-reported outcomes that affect quality of life, not only the usual clinical ones (SCDAA, August 2026).
When will the FDA decide on mitapivat for sickle cell disease?
The FDA's goal date is February 1, 2027, moved from November 1, 2026. The agency asked whether mitapivat needs a REMS safety program and treated Agios's answer as a major amendment. The FDA granted the application priority review in July 2026 and can act before the goal date.
Why was the mitapivat sickle cell decision delayed?
The FDA asked Agios on October 9, 2026 for information to decide whether a REMS, a required safety program, is needed for sickle cell disease. Agios answered on October 19 with about 9 more months of safety data. On October 28 the FDA classified that answer as a major amendment, which added 3 months to the review.
Would mitapivat need liver tests for sickle cell disease?
That will depend on the label, which does not exist yet for sickle cell disease. The thalassemia version, Aqvesme, requires liver tests before the first dose and every 4 weeks for 24 weeks through its REMS. Pyrukynd for PK deficiency recommends monthly liver tests for the first 6 months, without a REMS.
Did mitapivat reduce sickle cell pain crises?
It did not reduce them significantly. In the RISE UP Phase 3 trial, people on mitapivat had 2.62 pain crises a year and people on placebo had 3.05, a difference that was not statistically significant (p=0.12). The trial did meet its hemoglobin goal: 40.6% on mitapivat had a hemoglobin response compared with 2.9% on placebo.
Is mitapivat the same drug as Pyrukynd and Aqvesme?
Yes. Mitapivat is sold as Pyrukynd for pyruvate kinase deficiency, approved in 2022, and as Aqvesme for anemia in adults with thalassemia, approved in December 2025. Aqvesme uses the same 100mg twice-daily dose tested in sickle cell and carries a boxed warning for liver injury with a required safety program.
How is mitapivat different from Oxbryta?
They are different drugs with different targets. Mitapivat activates pyruvate kinase, an enzyme red blood cells use for energy. Both went to the FDA under accelerated approval on a hemoglobin result, but Oxbryta's approval rested on hemoglobin alone, while mitapivat's Phase 3 trial also tested pain crises for a full year and did not meet that goal. Oxbryta was withdrawn in September 2024 after later trials showed more crises and deaths.
Can you take mitapivat with hydroxyurea?
People on a stable dose of hydroxyurea were allowed in the RISE UP trial, and Agios reported that the lower transfusion rate on mitapivat held whether or not people took hydroxyurea. The FDA label will state how it can be used. How the 2 medicines would fit together for a particular person is a question for a hematologist.
What is the REIGNITE trial?
REIGNITE is the confirmatory Phase 3 trial the FDA requires for accelerated approval. It is enrolling about 159 people aged 12 and older with sickle cell disease, 2 on mitapivat for every 1 on placebo, and its main goal is the share who stay transfusion-free from week 4 through week 52. Agios dosed the first patient by July 2026.
Is etavopivat approved for sickle cell disease?
No. Etavopivat, from Novo Nordisk, met both main goals of its HIBISCUS Phase 3 trial in April 2026, including a 27% lower rate of pain crises, and Novo Nordisk said it plans to file for approval in the second half of 2026.
Can I join a trial if I take hydroxyurea?
Often, yes. Of 48 recruiting or upcoming sickle cell trials that set a hydroxyurea rule on September 29, 2026, 19 allowed it at a stable dose, most often after about 3 months on the same dose. Transplant and gene therapy trials usually ask for hydroxyurea to have failed, caused side effects or been declined, and 7 trials required stopping it first.
